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Abstract
Aims/hypothesis—Vitamin D and related genetic variants are associated with obesity and 
insulin resistance. We aimed to examine whether vitamin D metabolism-related variants affect 
changes in body weight and insulin resistance in response to weight-loss diets varying in 
macronutrient content.
Methods—Three vitamin D metabolism-related variants, DHCR7 rs12785878, CYP2R1 
rs10741657 and GC rs2282679, were genotyped in 732 overweight/obese participants from a 2 
year weight-loss trial (POUNDS Lost). We assessed genotype effects on changes in body weight, 
fasting levels of glucose and insulin, and HOMA-IR at 6 months (up to 656 participants) and 2 
years (up to 596 participants) in response to low-protein vs high-protein diets, and low-fat vs high-
fat diets.
Results—We found significant interactions between DHCR7 rs12785878 and diets varying in 
protein, but not in fat, on changes in insulin and HOMA-IR at both 6 months (p for interaction 
<0.001) and 2 years (p for interaction ≤0.03). The T allele (vitamin-D-increasing allele) of 
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DHCR7 rs12785878 was associated with greater decreases in insulin and HOMA-IR (p<0.002) in 
response to high-protein diets, while there was no significant genotype effect on changes in these 
traits in the low-protein diet group. Generalised estimating equation analyses indicated significant 
genotype effects on trajectory of changes in insulin resistance over the 2 year intervention in 
response to high-protein diets (p<0.001). We did not observe significant interaction between the 
other two variants and dietary protein or fat on changes in these traits.
Conclusions/interpretation—Our data suggest that individuals carrying the T allele of 
DHCR7 rs12785878 might benefit more in improvement of insulin resistance than noncarriers by 
consuming high-protein weight-loss diets.
Trial registration—ClinicalTrials.gov NCT00072995
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Diet intervention; Genetic variants; Insulin resistance; Vitamin D; Weight loss
Introduction
Vitamin D has a pleiotropic role in various metabolic functions beyond regulation of 
calcium and bone metabolism [1]. Compelling evidence has shown that low blood levels of 
25-hydroxyvitamin D (25(OH)D), an indicator of circulating vitamin D levels, is associated 
with obesity, insulin resistance and an increased risk of type 2 diabetes [2–8]. A recent 
genome-wide association study (GWAS) identified that variants in several genes involved in 
vitamin D metabolism, such as DHCR7, CYP2R1 and GC, were associated with 25(OH)D 
levels [9]. The DHCR7 gene encodes 7-dehydrocholesterol reductase (DHCR7), which 
converts 7-dehydrocholesterol (a precursor both for vitamin D and for cholesterol) to 
cholesterol, thereby reducing the availability of this precursor for cutaneous synthesis into 
vitamin D by the action of sunlight [10]. The enzyme encoded by CYP2R1, cytochrome 
P450, family 2, subfamily R, polypeptide 1, is a key vitamin D 25-hydroxylase [11]. The 
GC gene encodes vitamin D binding protein, which plays a major role in vitamin D transport 
and storage [12]. However, the causal relationships between vitamin D levels and 
cardiometabolic diseases inferred by Mendelian randomisation studies remain unclear [4, 
13–15]. For example, a vitamin D genetic score (based on variants in DHCR7 and CYP2R1) 
was found to be associated with blood pressure and hypertension [13], but this score was not 
associated with obesity in a previous analysis [4]. Afzal et al [14] reported that genetic 
variants associated with lower plasma 25(OH)D concentrations are associated with an 
increased risk of type 2 diabetes, while another study did not observe such associations [15]. 
Thus, examining whether vitamin D metabolism-related genetic variants affect long-term 
changes in body weight, glucose metabolism and insulin resistance may help explain the 
role of vitamin D in cardiometabolic diseases.
It has been shown that DHCR7 activity and DHCR7 gene expression could be regulated by 
vitamin D or other dietary nutrients [16–19], suggesting potential interactions between 
dietary factors and vitamin D metabolism-related genes. Protein-rich and fat-rich foods are 
the main sources of naturally occurring cholecalciferol (vitamin D3) [20]; therefore, we 
hypothesised that diets varying in protein or fat content might differentially affect the effect 
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of vitamin D metabolism-related variants on body weight and related metabolic traits. Thus, 
we tested this hypothesis among 732 participants in a 2 year randomised dietary intervention 
weight-loss trial, the Preventing Overweight Using Novel Dietary Strategies Trial 
(POUNDS Lost) [21]. We examined the effects of three GWAS-identified vitamin D 
metabolism-related variants in the DHCR7, CYP2R1 and GC genes on weight loss and 
improvement of glucose and insulin metabolism in response to diets varying in protein or fat 
content.
Methods
Study participants
POUNDS Lost is a randomised intervention trial in which 811 overweight or obese 
participants aged 30–70 years were assigned to one of four energy-limited diets over a 2 
year period, in order to compare the effects of energy-reduced diets with different 
compositions of fat, protein and carbohydrate on weight loss. The detailed study design and 
methods have been described before [21]. Participants were excluded from this trial if they 
had diabetes treated with medication or unstable cardiovascular disease, if they used 
medications influencing body weight or if they expressed insufficient motivation at baseline 
examination. According to the two-by-two factorial design, two diets were low fat (20% of 
energy derived from fat) and two were high fat (40% of energy derived from fat), and two 
were average protein (15% of energy derived from protein) and two were high protein (25% 
of energy derived from protein). All these diets consisted of similar foods and met 
guidelines for cardiovascular health. The caloric prescription for each participant 
represented a deficit of 3138 kJ (750 kcal)/day from baseline, as calculated from the 
participant’s resting energy expenditure and activity level.
After 2 years, 80% of the participant (n=645) completed the trial. The main results of weight 
loss in POUNDS Lost have been reported before [21]. Most of the weight loss occurred in 
the first 6 months, and the amount of weight loss after 2 years was similar among different 
diet groups. Both self-reported dietary data and biomarkers confirmed that participants 
modified their intake of macronutrients in the direction of the assigned goals [21]. In the 
current study, a total of 732 participants with genotype data available were included (90% of 
the participants in POUNDS Lost). At 6 months, 656 participants with body weight 
measurement and 626 participants with blood samples were included for the analyses. At 2 
years, 596 participants with body weight measurements and 533 participants with blood 
samples were included for the analyses.
The study was approved by the human participants committee at the Harvard T.H. Chan 
School of Public Health and Brigham and Women’s Hospital, Boston, MA, and the 
Pennington Biomedical Research Center of the Louisiana State University System, Baton 
Rouge, LA, and by a data and safety monitoring board appointed by the National Heart, 
Lung, and Blood Institute. Written informed consent was provided by all participants.
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Measurements
At baseline examination and at 6 month and 2 year visits, body weight for each participant 
was measured in the morning before breakfast. Height was measured at baseline only. BMI 
was presented as weight/height2 (kg/m2). In the current study, ethnicity was self-reported 
and grouped as white, black and others. Fasting blood samples were collected at baseline 
and at 6 month and 2 year visits. Fasting glucose and insulin were measured using an 
immunoassay with chemiluminescent detection on the Immulite Analyzer (Diagnostic 
Products Corporation, Los Angeles, CA, USA). Analyses of glucose and insulin were 
performed at the Clinical Laboratory at Pennington Biomedical Research Center of the 
Louisiana State University System. Insulin resistance was estimated by HOMA-IR [22]: 
fasting glucose (mmol/l) × fasting insulin (pmol/l)/156.3. Dietary intake was assessed by a 
review of the 5 day diet records at baseline and by 24 h recall during a telephone interview 
on three nonconsecutive days at 6 months and at 2 years [21].
Genotyping
DNA was extracted from the buffy coat fraction of centrifuged blood using the QIAmp 
Blood Kit (Qiagen, Chatsworth, CA, USA). Three lead single nucleotide polymorphisms 
(SNPs) in vitamin-D-related loci, DHCR7 rs12785878 (p=2.1×10−27), CYP2R1 rs10741657 
(p=3.3×10−20) and GC rs2282679 (p=1.9×10−109), identified through a previous large-scale 
GWAS for 25-hydroxyvitamin D concentrations (up to 33,996 individuals) [9], were 
selected in the current study. Genotyping was performed using the OpenArray SNP 
Genotyping System (BioTrove, Woburn, MA, USA). The genotype success rate was 99%. 
Replicate quality control samples (10%) were included and genotyped with >99% 
concordance. The genotype frequencies in all participants or in white participants were in 
Hardy–Weinberg equilibrium (p >0.05).
Statistical analysis
General linear models for continuous variables and χ2 tests for categorical variables were 
applied for the comparison according to genotype groups at baseline. To improve normality, 
fasting insulin and HOMA-IR were log10 transformed before analyses. The primary 
outcomes were changes in body weight, fasting insulin, glucose and HOMA-IR over the 
time the participants remained in the trial. General linear models were applied to compare 
changes from baseline in these outcomes across genotype groups according to diet groups 
(high-protein vs low-protein diets and high-fat vs low-fat diets) at 6 month and 2 year visits, 
adjusted for age, sex, ethnicity and baseline value for the respective outcome. We used 
additive inheritance models (e.g. DHCR7 rs12785878 genotype groups were coded as 0, 1 
and 2 in continuous form for GG, GT and TT) in the analyses. To test potential gene–diet 
intervention interactions, a genotype-by-diet interaction term (e.g. DHCR7 rs12785878 
genotype × high-/low-protein diet group) was included in the models. In addition, 
generalised estimating equation methods were applied to test genotype effects on the 
trajectory of changes in fasting insulin and HOMA-IR over the 2 year intervention. As 
HOMA-IR was calculated on the basis of glucose and insulin, and the endpoints at 6 months 
and 2 years were correlated, we did not treat them as independent variables. All statistical 
analyses were performed in SAS version 9.4 (SAS Institute, Cary, NC, USA).
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Bonferroni’s adjustment was applied to adjust p values for 18 independent tests (3 
independently measured traits [body weight, glucose and insulin] × 3 genetic variants × 2 
diet comparisons) at each time point (p<0.0028). We used Quanto 1.2.4 (University of 
Southern California, Los Angeles, CA, USA; http://biostats.usc.edu/Quanto.html) to 
estimate the detectable effect sizes of genotype-by-diet interactions. For the DHCR7 
rs12785878 variant, the study had 80% power to detect gene–diet interaction effect sizes of 
2.55 and 3.53 kg for weight loss, 0.22 and 0.25 mmol/l for changes in fasting glucose levels, 
0.22 and 0.24 log-transformed unit for changes in fasting insulin levels, and 0.24 and 0.26 
log-transformed unit for changes in HOMA-IR at 6 months and 2 years, respectively, at a 
p<0.0028 level. More power calculation results are shown in electronic supplementary 
material (ESM) Table 1.
Results
Baseline characteristics
Table 1 shows the baseline characteristics of participants according to the genotypes of 
DHCR7 rs12785878, CYP2R1 rs10741657 and GC rs2282679. For all three genetic variants, 
the genotype frequencies were similar between men and women, high- and low-protein diet 
groups and high- and low-fat diet groups, while they differed among ethnic groups (p≤0.05). 
In addition, the CYP2R1 rs10741657 variant was associated with fasting glucose levels at 
baseline.
Weight loss and dietary intake
Consistent with the entire POUNDS Lost [21], the amount of weight loss was similar 
between the low- and high-protein diet groups (6 months: 6.5 vs 6.6 kg, p=0.71; 2 years: 3.6 
vs 4.5 kg, p=0.11) and between the low- and high-fat diet groups (6 months: 6.7 vs 6.4 kg, 
p=0.52; 2 years: 4.1 vs 3.9 kg, p=0.76) among study participants (ESM Table 2). The 
reported dietary intakes confirmed that participants modified their intake of macronutrients 
in the direction of the intervention (ESM Table 3). Participants in the high-protein diet 
groups and in the high-fat diet groups reported higher dietary protein intake and higher fat 
intake than those in the low-protein diet groups and in the low-fat diet groups, respectively 
(all p<0.05).
Genotypes and changes in weight, glucose and insulin resistance by diet groups
We observed significant interactions between DHCR7 rs12785878 and high-/low-protein 
diet intervention on changes in fasting insulin (p for interaction=0.0008) and HOMA-IR (p 
for interaction=0.0009) at 6 months, adjusted for age, sex, ethnicity and the baseline value 
for the respective outcome trait (Table 2). In the high-protein diet groups, the T-allele of 
DHCR7 rs12785878 was associated with greater decreases in fasting insulin (p=0.0009) and 
HOMA-IR (p=0.002; Table 2 and Fig. 1). These genotype–diet interactions and genotype 
effects remained significant after correcting for multiple testing (p<0.0028). In the low-
protein diet groups, there was no significant genotype effect on changes in fasting insulin or 
HOMA-IR (p ≥0.14). Results were similar but attenuated at 2 years (Table 2 and Fig. 1), and 
there were nominally significant genotype–diet interactions on changes in fasting insulin (p 
Qi et al. Page 5
Diabetologia. Author manuscript; available in PMC 2016 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
for interaction =0.03) and HOMA-IR (p for interaction =0.02). These results did not change 
materially after further adjustment for weight loss (ESM Table 4).
For genetic variants in CYP2R1 and GC, we did not find significant genotype–diet 
interactions or genotype effects on changes in body weight, fasting glucose, fasting insulin 
or HOMA-IR at 6 months or 2 years (all p>0.05; Table 2).
We also examined interaction between genetic variants and high-/low-fat diet interventions 
on changes in these metabolic traits (ESM Table 5). There were nominally significant 
interactions between CYP2R1 rs10741657 and dietary fat on changes in fasting insulin and 
HOMA-IR at both 6 months and 2 years (p for interaction <0.05). In the low-fat diet groups, 
the A allele of CYP2R1 rs10741657 showed a trend to be associated with less decreases in 
fasting insulin and HOMA-IR at both 6 months (p=0.04) and 2 years (p=0.03), while no 
genotype effect was observed in the high-fat diet groups. However, these results did not pass 
a threshold of p<0.0028 after correcting for multiple testing.
As the majority of participants in this study were white (~80%), we further performed 
sensitivity analyses by excluding other ethnic groups. Similar results were observed when 
the analyses were restricted to the white participants.
Trajectory of changes in insulin resistance by DHCR7 rs12785878 in response to high-/
low-protein diets
We then assessed the genotype of DHCR7 rs12785878 by time effect on improvement of 
insulin resistance over the 2 year intervention in the participants assigned to the high- and 
low-protein diets (Fig. 2). In the high-protein diet group, participants carrying the T-allele of 
DHCR7 rs12785878 (TT and TG genotypes) had a greater improvement of fasting insulin 
(p<0.0001) and HOMA-IR (P=0.0009) than non-T-carriers (GG genotype) across the 2 year 
intervention. As expected, the genetic associations with changes in fasting insulin and 
HOMA-IR appeared to be more pronounced at 6 months than at 2 years. In the low-protein 
diet group, there was no significant genotype effect on the trajectory of changes in insulin 
resistance over the 2 year intervention (p≥0.11). Similar results were observed when the 
analyses were restricted to the white participants.
Discussion
In this large, 2 year randomised dietary weight-loss intervention trial, we found significant 
interactions between a vitamin-D-related genetic variant DHCR7 rs12785878 and dietary 
protein intake on changes in fasting insulin and HOMA-IR; furthermore, results were 
consistent for short-term (6 months) and long-term (2 years) changes. The T-allele of 
DHCR7 rs12785878 was associated with greater improvement of insulin resistance among 
individuals who were assigned to the high-protein diets.
A large body of evidence implicates the DHCR7 gene in insulin resistance through effects 
on vitamin D levels. The T allele of DHCR7 rs12785878 was strongly associated with 
higher circulating 25(OH)D levels in GWAS (p=2.1×10−27) [9], while lower 25(OH)D 
levels have been associated with obesity, insulin resistance, systemic inflammation and the 
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risk of diabetes [2–8]. A recent Mendelian randomisation study found that the DHCR7 allele 
score but not the CYP2R1 allele score was associated with the risk of type 2 diabetes [14]. 
Several indices of insulin resistance were found to be significantly different across DHCR7 
rs12785878 genotypes in women with polycystic ovary syndrome [23]. In addition, DHCR7 
genetic variation was recently reported to interact with type 2 diabetes status to influence 
subclinical atherosclerosis [24]. However, no studies have investigated the interactions 
between DHCR7 genetic variants and diet/lifestyle factors in relation to cardiometabolic 
traits.
Although the mechanism underlying the observed DHCR7 rs12785878 gene–dietary protein 
interaction is unclear, several potential biological processes might be implicated. A perfect 
proxy SNP of DHCR7 rs12785878 (r2=1) has been found to modulate DHCR7 mRNA 
levels in liver [24]. In addition, protein-rich foods (e.g. fish, dairy if fortified and meat to a 
lesser extent) are the main sources of naturally occurring cholecalciferol (vitamin D3) [20], 
and cholecalciferol could suppress DHCR7 activity in human skin cells [19]. In POUNDS 
Lost, the difference between high- and low-protein diets is mainly from the difference in 
consumption of skinless turkey, lean beef and skimmed/nonfat milk, while the difference 
between high- and low-fat diets is mainly from the difference in consumption of walnuts and 
olive oil [21]. Thus, there might be a greater difference in vitamin D content between high- 
and low-protein diets than that between high- and low-fat diets. However, we could not 
exclude the possibility that other dietary nutrients might be also involved, since it has been 
suggested that DHCR7 gene expression might be regulated by dietary alpha-tocopherol [16], 
cholestyramine-plus-Lovastatin diet [17], and soy protein [18] in rats. In addition, dietary 
protein and amino acids are important modulators of glucose metabolism and insulin 
resistance [25–27]. Taken together, we speculate that cholecalciferol and/or other nutrients 
from protein-rich foods may interact with DHCR7 rs12785878 (or a causal variant indicated 
by this SNP) to influence DHCR7 function, thereby affecting vitamin D levels and 
eventually modifying the effects on changes in insulin resistance.
Diminished adherence occurred between 6 months and 2 years in POUND Lost [21]; 
therefore, it was not surprising that the genetic effects on changes in insulin resistance were 
attenuated at 2 years. Improvement of insulin resistance has been associated with changes in 
body weight in this intervention study. However, we did not find significant gene–diet 
interaction or genetic effects on changes in body weight, although it has been previously 
suggested that adiposity might be involved in the relationships between vitamin-D-related 
variants, 25(OH)D levels and type 2 diabetes [14]. Moreover, the genetic effects on 
improvement of insulin resistance were independent of weight loss, suggesting other 
pathways might be involved.
We did not find strong evidence for interactions between the other two vitamin-D-related 
genetic variants, CYP2R1 rs10741657 and GC rs2282679, and dietary interventions on 
changes in body weight or glucose/insulin metabolism in this 2 year weight-loss trial. Both 
genes have been largely implicated in vitamin D metabolism, and CYP2R1 rs10741657 
(p=3.3×10−20) and GC rs2282679 (p=1.9×10−109) were also strongly associated with 
circulating 25(OH)D levels in GWAS [9]. However, a recent study found that the expression 
levels of CYP2R1 in adipose tissues did not change during diet-induced weight loss [28]. 
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Nevertheless, further studies are warranted to validate the observed nominally significant 
interactions between CYP2R1 rs10741657 and dietary fat on changes in fasting insulin and 
HOMA-IR. It has been suggested that the quality of dietary fat influences glucose 
metabolism and insulin resistance [29]. However, it should be noted that diets varying in fat 
content (low-fat diets or high-fat diets) are not emphasised in the nutritional therapy 
recommendations for diabetes [30], and both extremely high- and low-fat diets might not be 
beneficial regarding glucose metabolism in diabetes [29].
To the best of our knowledge, this is the first study to show significant interactions between 
vitamin-D-related genetic variation and dietary protein on improvement of insulin resistance 
in a large and long-term randomised trial. Previous evidence has suggested the important 
implications of vitamin D in insulin resistance and type 2 diabetes. Our findings provide 
new insight into the utility of using knowledge of vitamin-D-related genetic variation to 
improve personalised dietary interventions. However, several limitations of this study 
should be addressed. We did not measure circulating vitamin D or 25(OH)D concentrations 
in this study, which limited our analysis to examine the role of vitamin D levels in the gene–
diet interaction and explore potential underlying mechanisms. Although our major findings 
remained significant after adjustment for multiple tests, replication of these results is needed 
in future. In addition, the majority of participants are white (80%) in our study and thus 
further studies are needed in other ethnic groups, since significant ethnic differences in 
circulating vitamin D levels and related genetic variants have been acknowledged [31].
In summary, our data indicate that dietary protein may modify the effect of the DHCR7 
rs12785878 variant on changes in insulin resistance over a 2 year dietary intervention. 
Individuals carrying the T allele (vitamin-D-increasing allele) of DHCR7 rs12785878 might 
benefit more in improvement of insulin resistance than noncarriers by consuming high-
protein weight-loss diets. Our findings of gene–protein dietary interaction are biologically 
plausible, provide additional evidence for the roles of vitamin D in insulin resistance, and 
suggest new insights into effective strategies for type 2 diabetes prevention and intervention.
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Fig. 1. 
Changes in insulin (a, b) and HOMA-IR (c, d) by DHCR7 rs12785878 genotype in response 
to low-protein diets and high-protein diets at 6 months and 2 years. Black bars, DHCR7 
rs12785878 TT genotype; grey bars, DHCR7 rs12785878 TG genotype; white bars, DHCR7 
rs12785878 GG genotype. Dara are means ± SE, adjusted for age, sex, ethnicity and 
baseline value for the respective outcome traits. p=0.0008 and 0.03 for interactions between 
DHCR7 rs12785878 and diet intervention on changes in fasting insulin at 6 months (a) and 2 
years (b), respectively. p=0.0009 and 0.02 for interactions between DHCR7 rs12785878 and 
diet intervention on changes in HOMA-IR at 6 months (c) and 2 years (d), 
respectively. †p=0.0009 and ‡p=0.002 for genotype effects on changes in insulin (a) and 
HOMA-IR (c), respectively, at 6 months in the high-protein diet groups
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Fig. 2. 
Trajectory of changes in insulin and HOMA-IR by DHCR7 rs12785878 genotype in 
response to low-protein diets (a, c) and high-protein diets (b, d) over a 2 year intervention. 
Black circle and solid line, DHCR7 rs12785878 TT genotype; grey circle and dashed line, 
DHCR7 rs12785878 TG genotype; white circle and dotted line, DHCR7 rs12785878 GG 
genotype. Data are means ± SE, adjusted for age, sex, ethnicity and baseline value for the 
respective outcome traits. †p<0.0001 and ‡p=0.0009 for genotype effects on changes in 
insulin (b) and HOMA-IR (d), respectively, in the high-protein diet groups
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